Jerry Pelletier Selected Research

Eukaryotic Initiation Factor-4E

10/2021	Assessing eukaryotic initiation factor 4F subunit essentiality by CRISPR-induced gene ablation in the mouse.
1/2018	Beyond molecular tumor heterogeneity: protein synthesis takes control.
1/2016	Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status.
9/2014	Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.
11/2013	Suppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopecia.
1/2012	Eukaryotic initiation factor 4F: a vulnerability of tumor cells.
3/2011	Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
12/2009	Inhibitors of translation initiation as cancer therapeutics.
11/2009	Translation initiation: a critical signalling node in cancer.
1/2009	Altering chemosensitivity by modulating translation elongation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jerry Pelletier Research Topics

Disease

60	Neoplasms (Cancer) 05/2022 - 03/2004
18	Lymphoma (Lymphomas) 12/2021 - 03/2004
13	Carcinogenesis 01/2021 - 03/2004
4	Melanoma (Melanoma, Malignant) 12/2021 - 11/2010
3	Breast Neoplasms (Breast Cancer) 11/2019 - 06/2009
3	Genomic Instability 01/2019 - 08/2014
3	Virus Diseases (Viral Diseases) 01/2019 - 08/2005
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017 - 01/2014
3	Neoplasm Metastasis (Metastasis) 12/2016 - 03/2011
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 01/2016
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 01/2019
2	Hypoxia (Hypoxemia) 01/2018 - 06/2013
2	Glioma (Gliomas) 06/2017 - 09/2016
2	Infections 10/2015 - 05/2013
2	Multiple Myeloma 08/2015 - 09/2014
2	Cachexia 06/2012 - 02/2012
2	Starvation 09/2011 - 07/2008
2	Wilms Tumor (Wilm's Tumor) 03/2005 - 11/2002
1	Experimental Melanoma 12/2021
1	Neuroblastoma 01/2021
1	Memory Disorders (Memory Loss) 10/2020
1	Rhabdoid Tumor (Rhabdoid Tumors) 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2019
1	Malaria 07/2019
1	Ototoxicity 01/2019
1	Hearing Loss (Hearing Impairment) 01/2019
1	Small Cell Carcinoma 01/2019
1	Hepatitis C 01/2019
1	Retinoblastoma (Glioblastoma, Retinal) 01/2019
1	Atherosclerosis 01/2018
1	Plague (Bubonic Plague) 01/2018
1	Pathologic Processes 01/2018
1	Triple Negative Breast Neoplasms 01/2017
1	Head and Neck Neoplasms (Head and Neck Cancer) 09/2016

Drug/Important Bio-Agent (IBA)

24	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2002
16	Eukaryotic Initiation Factor-4EIBA 10/2021 - 03/2004
12	Peptide Initiation Factors (Initiation Factor)IBA 01/2022 - 12/2007
12	Eukaryotic Initiation Factor-4F (EIF4F)IBA 01/2020 - 10/2009
9	Pharmaceutical PreparationsIBA 01/2021 - 03/2004
7	Messenger RNA (mRNA)IBA 01/2019 - 09/2011
6	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 01/2009
6	silvestrolIBA 09/2014 - 07/2008
6	Sirolimus (Rapamycin)FDA Link 08/2008 - 03/2004
4	Biological ProductsIBA 10/2020 - 01/2016
4	Phosphotransferases (Kinase)IBA 01/2020 - 12/2007
4	DNA (Deoxyribonucleic Acid)IBA 06/2017 - 04/2004
3	RNA Helicases (RNA Helicase)IBA 05/2022 - 07/2013
3	Small Interfering RNA (siRNA)IBA 01/2022 - 07/2012
3	ChromatinIBA 01/2021 - 03/2005
3	Mechanistic Target of Rapamycin Complex 1IBA 10/2020 - 08/2008
3	Cyclin D1IBA 01/2020 - 01/2019
3	RNA (Ribonucleic Acid)IBA 01/2019 - 04/2013
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 09/2014
3	Cytostatic AgentsIBA 06/2017 - 11/2010
2	AntibodiesIBA 12/2021 - 01/2017
2	Eukaryotic Initiation Factor-4A (Eukaryotic Initiation Factor 4A)IBA 11/2019 - 01/2019
2	Complex MixturesIBA 07/2019 - 01/2017
2	Harmine (Telepathine)IBA 06/2017 - 06/2017
2	norharmanIBA 06/2017 - 06/2017
2	Antineoplastic Agents (Antineoplastics)IBA 01/2016 - 01/2015
2	ABT-737IBA 01/2015 - 04/2013
2	TOR Serine-Threonine KinasesIBA 09/2014 - 08/2006
2	pateamine AIBA 06/2012 - 12/2009
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 04/2010 - 07/2008
2	TensinsIBA 04/2010 - 07/2008
2	Transcription Factors (Transcription Factor)IBA 04/2004 - 11/2002
1	EpitopesIBA 12/2021
1	VaccinesIBA 12/2021
1	Carrier Proteins (Binding Protein)IBA 01/2021
1	Eukaryotic Initiation FactorsIBA 01/2021
1	Ribosomal Proteins (Ribosomal Protein)IBA 01/2021
1	Paclitaxel (Taxol)FDA LinkGeneric 10/2020
1	CyclinsIBA 11/2019
1	palbociclibIBA 11/2019
1	Estrogen ReceptorsIBA 11/2019
1	Chloroquine (Aralen)FDA LinkGeneric 07/2019
1	cleistenolideIBA 07/2019
1	dichamanetinIBA 07/2019
1	aglaroxin CIBA 01/2019
1	AminoglycosidesIBA 01/2019
1	Deubiquitinating EnzymesIBA 01/2019
1	venetoclaxIBA 01/2019
1	Ubiquitin-Specific ProteasesIBA 01/2019
1	Nuclear Proteins (Protein, Nuclear)IBA 01/2019
1	Immune Checkpoint InhibitorsIBA 01/2018
1	HDL LipoproteinsIBA 01/2018
1	DesmocollinsIBA 01/2018
1	Eukaryotic Initiation Factor-3IBA 06/2017
1	Antiviral Agents (Antivirals)IBA 01/2017
1	6-pyruvoyltetrahydropterin synthase (PTPS)IBA 01/2017
1	Interleukin-12 (IL 12)IBA 01/2017
1	Amaryllidaceae AlkaloidsIBA 09/2016
1	5,10b-ethanophenanthridineIBA 09/2016
1	crinineIBA 09/2016
1	AlkaloidsIBA 09/2016
1	MicroRNAs (MicroRNA)IBA 07/2016
1	IntegrinsIBA 01/2016

Therapy/Procedure

16	Therapeutics 01/2020 - 03/2004
10	Drug Therapy (Chemotherapy) 01/2019 - 03/2004
1	Immunotherapy 01/2017